Eton Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Eton Pharmaceuticals Inc ETON.OQ reported quarterly adjusted earnings of 7 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of three analysts for the quarter was for earnings of 5 cents per share. Wall Street expected results to range from -1 cents to 13 cents per share.

• Revenue rose 116.9% to $17.28 million from a year ago; analysts expected $15.13 million.

• Eton Pharmaceuticals Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $1.57 million.

• Eton Pharmaceuticals Inc shares had risen by 33.7% this quarter and gained 30.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 100% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $26.00

This summary was machine generated from LSEG data May 13 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)